As Passed by the House. Regular Session Sub. H. B. No

Similar documents
As Passed by the House. Regular Session H. B. No

As Passed by the Senate. Regular Session Sub. H. B. No

Sub. S.B. 119 As Passed by the Senate

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

A Bill Regular Session, 2015 SENATE BILL 717

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217

TEXAS COMPASSIONATE-USE ACT

Michigan Opioid Legislation Hospital Compliance Checklist

Naloxone Access Statutes

PROPOSED AMENDMENTS TO HOUSE BILL 3440

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Prescription Monitoring Program (PMP)

Dispensing and administration of emergency opioid antagonist without a

2016 Dr. Douglas H. Kay CPE Symposium

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

State, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

AN ACT. relating to the medical use of low-thc cannabis and the regulation. of related organizations and individuals; requiring a dispensing

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

CRITICAL POLICY REFERENCE MANUAL FILE CODE: X Monitored X Mandated Sample Policy X Other Reasons

S 0332 S T A T E O F R H O D E I S L A N D

SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the

S 2356 SUBSTITUTE A AS AMENDED ======== LC004564/SUB A/3 ======== S T A T E O F R H O D E I S L A N D

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

Naloxone Access Statutes

btute PUBLIC CHAPTER NO. 1039

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

California. Prescribing and Dispensing Profile. Research current through November 2015.

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

SOUTH DAKOTA BOARD OF REGENTS. Policy Manual

Proposed Revision to Med (i)

ASSEMBLY, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED MAY 15, 2014

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

CHAPTER House Bill No. 1429

CHAPTER NINE INSULIN AND GLUCAGON ADMINISTRATION

CERTIFICATION OF ENROLLMENT ENGROSSED SUBSTITUTE SENATE BILL th Legislature 2007 Regular Session

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Supplement No. 1 published with Extraordinary Gazette No. 65 dated 19 th August, 2016.

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

H 7816 S T A T E O F R H O D E I S L A N D

SECTION PRESCRIPTIONS

[First Reprint] ASSEMBLY, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 4, 2016

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

[CORRECTED COPY] CHAPTER 115

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled. House Bill 3440

As Introduced. 132nd General Assembly Regular Session S. B. No

ASSEMBLY, No. 542 STATE OF NEW JERSEY. 218th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION

Good Samaritan and Naloxone Bill Status Report Carryover 2016 and Special Sessions

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 8, 2016

Rule Governing the Prescribing of Opioids for Pain

Title 32: PROFESSIONS AND OCCUPATIONS

For An Act To Be Entitled. Subtitle

North Dakota Board of Pharmacy

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Policy / Drug and Alcohol-Free Workshops

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243

As Introduced. 130th General Assembly Regular Session H. B. No A B I L L

State, District, or Territory Criteria for Mandatory Query of PDMP

NC General Statutes - Chapter 90 Article 5E 1

POLICY ON SUBSTANCE ABUSE FOR FACULTY, STAFF, AND STUDENTS

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

NOTICE OF INTENT. Department of Health and Hospitals Board of Dentistry

Referred to Committee on Health and Human Services. SUMMARY Establishes an opioid overdose prevention policy for Nevada.

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

WHAT YOU NEED TO KNOW TO ABOUT AB 474

A. The unlawful possession, use, distribution, manufacture, or dispensing of illicit drugs on EVMS property or at an EVMS off-campus activity.

HEB Pharmacy Conference October 25, 2014

The State of Maryland Executive Department

Legal Considerations for. Immunizations

I. POLICY: DEFINITIONS: Applicant: Any individual who applies for employment with the Department of Juvenile Justice.

OREGON MEDICAL MARIJUANA ACT

3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott,

24. 95* Table of Contents. CE for Ohio Nursing Professionals. All 24 Hrs ONLY. Elite. Student Final Examination Answer Sheet Page 133

Appendix F Federation of State Medical Boards

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2013 H 1 HOUSE BILL 933. Short Title: Informed Consent for HIV/AIDS Testing. (Public)

History Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.

UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB)

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

Workplace Drug and Alcohol Policy

MEDICAL MARIJUANA USE

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 2760

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Workplace Drug and Alcohol Policy

Policy \ \ Medical (Palliative) Use of Marijuana

POL HR CDL DRUG AND ALCOHOL TESTING PLAN Page 1 of 8 POLICY. See Also: POL-0409-HR; PRO HR; PRO HR Res

As Introduced. 132nd General Assembly Regular Session H. B. No

Transcription:

132nd General Assembly Regular Session Sub. H. B. No. 167 2017-2018 Representative Edwards Cosponsors: Representatives Householder, Anielski, Antani, Antonio, Arndt, Blessing, Brenner, Brown, Butler, Carfagna, Clyde, Craig, Cupp, Dever, Gavarone, Ginter, Gonzales, Green, Hagan, Hambley, Henne, Hoops, Hughes, Ingram, Johnson, Keller, Kick, Landis, Lanese, Lang, Leland, Manning, McClain, Merrin, Miller, O'Brien, Patterson, Patton, Pelanda, Perales, Reineke, Riedel, Roegner, Rogers, Romanchuk, Ryan, Scherer, Schuring, Seitz, Sheehy, Smith, T., Stein, Thompson, West, Wiggam, Wilkin, Young, Speaker Smith A B I L L To amend sections 4723.52, 4730.56, 4731.83, and 5119.363, to amend, for the purpose of adopting a new section number as indicated in parentheses, section 3715.08 (3719.064), and to enact sections 3719.063 and 4729.283 of the Revised Code regarding naltrexone and medication-assisted treatment. 1 2 3 4 5 6 7 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO: Section 1. That sections 4723.52, 4730.56, 4731.83, and 5119.363 be amended, section 3715.08 (3719.064) be amended for the purpose of adopting a new section number as indicated in parentheses, and sections 3719.063 and 4729.283 of the Revised Code be enacted to read as follows: Sec. 3719.063. In the absence of gross negligence or intentional misconduct, a person who administers the drug 8 9 10 11 12 13 14

Sub. H. B. No. 167 Page 2 naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met: (A) The individual to whom the drug is administered is unable to have it administered as follows: (1) By a person who routinely administers the drug to the individual; (2) At the facility at which the drug is routinely administered to the individual; (3) Under the direction of the drug's prescriber. (B) The person who administers the drug under this section is legally authorized to administer it by injection but is not the prescriber of the drug or one who routinely administers it to the individual. (C) The drug is provided to the person who administers it under this section in either of the following ways: (1) By the individual to whom it is administered; (2) By the pharmacy that has a record of a prescription for the drug in the name of the individual to whom it is administered. (D) The person who administers the drug under this section is authorized to do so by that person's employer or the facility at which the drug is administered. Sec. 3715.08 3719.064. (A) As used in this section: (1) "Medication-assisted treatment" has the same meaning 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

Sub. H. B. No. 167 Page 3 as in section 340.01 of the Revised Code. (2) "Prescriber" means any of the following: (a) An advanced practice registered nurse who holds a current, valid license issued under Chapter 4723. of the Revised Code and is designated as a clinical nurse specialist, certified nurse-midwife, or certified nurse practitioner; (b) A physician authorized under Chapter 4731. of the Revised Code to practice medicine and surgery or osteopathic medicine and surgery; (c) A physician assistant who is licensed under Chapter 4730. of the Revised Code, holds a valid prescriber number issued by the state medical board, and has been granted physician-delegated prescriptive authority. (3) "Qualifying practitioner" has the same meaning as in section 303(g)(2)(G)(iii) of the "Controlled Substances Act of 1970," 21 U.S.C. 823(g)(2)(G)(iii), as amended. (B) Before initiating medication-assisted treatment, a prescriber shall give the patient or the patient's representative information about all drugs approved by the United States food and drug administration for use in medication-assisted treatment. The information must be provided both orally and in writing. The prescriber or the prescriber's delegate shall note in the patient's medical record when this information was provided and make the record available to employees of the board of nursing or state medical board on their request. If the prescriber is not a qualifying practitioner and the patient's choice is treatment with a controlled substance containing buprenorphine and the prescriber determines that such 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70

Sub. H. B. No. 167 Page 4 treatment is clinically appropriate and meets generally accepted standards of medicine, the prescriber shall refer the patient to a qualifying practitioner. If the patient's choice is methadone treatment and the prescriber determines that such treatment is clinically appropriate and meets generally accepted standards of medicine, the prescriber shall refer the patient to a community addiction services provider licensed under section 5119.391 of the Revised Code. In either case, the prescriber or the prescriber's delegate shall make a notation in the patient's medical record naming the practitioner or provider to whom the patient was referred and specifying when the referral was made. Sec. 4723.52. (A) As used in this section: (1) "Community addiction services provider" has the same meaning as in section 5119.01 of the Revised Code. (2) "Medication-assisted treatment" has the same meaning as in section 340.01 of the Revised Code. (B) An advanced practice registered nurse shall comply with section 3715.08 3719.064 of the Revised Code and rules adopted under section 4723.51 of the Revised Code when treating a patient for addiction with medication-assisted treatment or proposing to initiate such treatment. (C) An advanced practice registered nurse who fails to comply with this section shall treat not more than thirty patients at any one time with medication-assisted treatment even if the facility or location at which the treatment is provided is either of the following: (1) Exempted by divisions (B)(2)(a) to (d) of section 4729.553 of the Revised Code from being required to possess a category III terminal distributor of dangerous drugs license 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99

Sub. H. B. No. 167 Page 5 with an office-based opioid treatment classification; (2) A community addiction services provider that provides alcohol and drug addiction services that are certified by the department of mental health and addiction services under section 5119.36 of the Revised Code. Sec. 4729.283. (A) A pharmacist may dispense naltrexone without a written or oral prescription from a licensed health professional authorized to prescribe drugs if all of the following conditions are met: (1) The pharmacist is able to verify a record of a prescription for the injectable long-acting or extended-release form of naltrexone in the name of the patient who is requesting the drug, but the prescription does not provide for a refill or the time permitted by rules adopted by the state board of pharmacy for providing refills has elapsed. (2) The pharmacist is unable to obtain authorization to refill the prescription from the prescriber who issued it or another prescriber responsible for the patient's care. (3) In the exercise of the pharmacist's professional judgment: (a) The drug is necessary to continue the patient's therapy for substance use disorder. (b) Failure to dispense the drug to the patient could result in harm to the health of the patient. (B) Before dispensing naltrexone under this section, the pharmacist shall offer the patient the choice of receiving either the oral form or injectable long-acting or extendedrelease form, but only if both forms of the drug are available 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127

Sub. H. B. No. 167 Page 6 for dispensing at the time of the patient's request or within one day after the request. (C)(1) With respect to naltrexone dispensed in an oral form under this section, the pharmacist shall not dispense an amount that exceeds a five-day supply. (2) With respect to naltrexone dispensed in an injectable long-acting or extended-release form under this section, both of the following apply: (a) The pharmacist shall exercise professional judgment in determining the amount of the drug dispensed. (b) The pharmacist may administer the drug by injection to the patient but only in accordance with section 4729.45 of the Revised Code. (D) A pharmacist who dispenses naltrexone under this section shall do all of the following: (1) For one year after the date of dispensing, maintain a record in accordance with this chapter of the drug dispensed, including the amount and form dispensed, the original prescription number, the name and address of the patient and, if the individual receiving the drug is not the patient, the name and address of that individual; (2) Notify the prescriber who issued the prescription described in division (A)(1) of this section or another prescriber responsible for the patient's care not later than five days after the drug is dispensed; (3) If applicable, obtain authorization for additional dispensing from one of the prescribers described in division (D) (2) of this section. 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155

Sub. H. B. No. 167 Page 7 (E) A pharmacist shall exercise professional judgment in determining the number of times naltrexone may be dispensed under this section to the same patient. (F) This section does not limit the authority of a pharmacist to dispense a dangerous drug under section 4729.281 of the Revised Code. Sec. 4730.56. (A) As used in this section: (1) "Community addiction services provider" has the same meaning as in section 5119.01 of the Revised Code. (2) "Medication-assisted treatment" has the same meaning as in section 340.01 of the Revised Code. (B) A physician assistant shall comply with section 3715.08 3719.064 of the Revised Code and rules adopted under section 4730.55 of the Revised Code when treating a patient with medication-assisted treatment or proposing to initiate such treatment. (C) A physician assistant who fails to comply with this section shall treat not more than thirty patients at any one time with medication-assisted treatment even if the facility or location at which the treatment is provided is either of the following: (1) Exempted by divisions (B)(2)(a) to (d) of section 4729.553 of the Revised Code from being required to possess a category III terminal distributor of dangerous drugs license with an office-based opioid treatment classification; (2) A community addiction services provider that provides alcohol and drug addiction services that are certified by the department of mental health and addiction services under section 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183

Sub. H. B. No. 167 Page 8 5119.36 of the Revised Code. Sec. 4731.83. (A) As used in this section: (1) "Medication-assisted treatment" has the same meaning as in section 340.01 of the Revised Code. (2) "Physician" means an individual authorized by this chapter to practice medicine and surgery or osteopathic medicine and surgery. (B) A physician shall comply with section 3715.08 3719.064 of the Revised Code and rules adopted under section 4731.056 of the Revised Code when treating a patient with medicationassisted treatment or proposing to initiate such treatment. (C) A physician who fails to comply with this section shall treat not more than thirty patients at any one time with medication-assisted treatment even if the facility or location at which the treatment is provided is either of the following: (1) Exempted by divisions (B)(2)(a) to (d) of section 4729.553 of the Revised Code from being required to possess a category III terminal distributor of dangerous drugs license with an office-based opioid treatment classification; (2) A community addiction services provider that provides alcohol and drug addiction services that are certified by the department of mental health and addiction services under section 5119.36 of the Revised Code. Sec. 5119.363. The director of mental health and addiction services shall adopt rules governing the duties of boards of alcohol, drug addiction, and mental health services under section 340.20 of the Revised Code and the duties of community addiction services providers under section 5119.362 of the 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211

Sub. H. B. No. 167 Page 9 Revised Code. The rules shall be adopted in accordance with Chapter 119. of the Revised Code. The director shall adopt rules under this section that authorize the department of mental health and addiction services to determine an advanced practice registered nurse's, physician assistant's, or physician's compliance with section 3715.08 3719.064 of the Revised Code if such practitioner works for a community addiction services provider. Section 2. That existing section 3715.08, 4723.52, 4730.56, 4731.83, and 5119.363 of the Revised Code are hereby repealed. Section 3. This act shall be known as "Daniel's Law." 212 213 214 215 216 217 218 219 220 221 222 223